A randomised, parallel group, single blind, multicentre, 9-month, phase IV study in a primary care setting, comparing treatment guided by clinical symptoms and signs and NT-proBNP vs treatment guided by clinical symptoms and signs alone, in patients with heart failure and left ventricular systolic dysfunction The primary objective is to evaluate if 9 months of heart failure treatment guided by clinical symptoms, signs and NT-proBNP values is more effective to reduce the combination of cardiovascular (CV) d...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

An early phase study to evaluate the efficacy and safety of AZD1419 in patients with asthma To assess the efficacy of inhaled AZD1419 in eosinophilic asthma patients after withdrawal of controller treatment of ICS + LABA, by evaluating Time to loss of asthma control

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

An International, Multicenter, Double-blind, Randomized, Placebo-controlled, Phase IV Study of the Safety and Efficacy of Lithium versus Placebo as an add on to SEROQUEL XR™ (Quetiapine Fumarate) in Adult Patients with Acute Mania The primary objective is to evaluate the effectiveness of lithium compared to placebo as an add on to quetiapine XR in the treatment of acute mania in subjects with bipolar I disorder, as assessed by ...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A 12-week Open-Label, Randomised, Parallel-group, Multicentre, Phase IIIb Study to compare the Efficacy and Safety of rosuvastatin (CRESTOR) 10 mg and 20 mg in Combination with Ezetimibe 10 mg and Sivastatin 40 mg and 80 mg in Combination with Ezetimibe 10 mg (fixed dose combination) in Patients with Hypercholesterolaemia and Coronary Heart Disease (CHD) or a CHD Risk Equivalent, Atherosclerosis or a 10-year CHD Risk of >20% (GRAVITY) The primary objective of this study is to evaluate the LDL-C lowering efficacy of rosuvastatin 10 mg and 20 mg in combination with ezetimibe relative to that of simvastatin in a fixed dose combination...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Phase 2B study of multiple doses to evaluate the safety and treatment benefits of MEDI2070 in subjects with Crohn's Disease who have failed or are Intolerant to Anti Tumor Necrosis Factor-Alpha Therapy The primary objective of this study is to evaluate the efficacy of MEDI2070 versus placebo to induce clinical remission based on the CDAI score at Week 8 in subjects with moderate to severe CD who hav...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Étude D081FC00001-POLO : étude de phase 3, randomisée, en double aveugle, comparant l’efficacité et la tolérance d’un traitement d'entretien par olaparib administré seul par rapport à un placebo, chez des patients ayant un cancer pancréas métastatique avec mutation gBRCA n'ayant pas progressé sous chimiothérapie de première ligne à base de sel de platine. [essai clos aux inclusions] L’objectif de cette étude est de comparer l’efficacité et la tolérance d’un traitement d'entretien par olaparib administré seul par rapport à un placebo, chez des patients ayant un cancer pancréas mét...

• Pays France
• Organes Pancréas
• Spécialités Thérapies Ciblées

Intranasal zolmitriptan is effective and well tolerated in acute cluster headache Not provided at time of registration

• Pays Germany, Italy, United Kingdom
• Organes Aucun
• Spécialités Aucune

A Phase III, Randomized, Double-blinded, Parallel Group, Multi-centre Study to Assess the Efficacy and Safety of ZD6474 (ZACTIMA™) in Combination with Pemetrexed (Alimta®) versus Pemetrexed alone in Patients with Locally-Advanced or Metastatic (stage IIIB or IV) Non-Small Cell Lung Cancer (NSCLC) after Failure of 1st Line Anti-cancer Therapy The primary objective of this study is to demonstrate an improvement in PFS as assessed by RECIST criteria, for the combination of ZD6474 plus pemetrexed (Alimta®) compared with pemetrexed plus placeb...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A global study to compare the effects of fulvestrant and arimidex in a subset of patients with breast cancer Globalne badanie mające na celu porównanie działań fulwestrantu i arimideksu w podgrupie pacjentek z rakiem piersi To demonstrate superior progression free survival for patients treated with fulvestrant 500mg versus patients treated with anastrozole 1mg Wykazanie dłuższego czasu przeżycia bez progresji choro...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Olaparib as adjuvant treatment in patients with germline BRCA mutated high risk HER2 negative primary breast cancer. Olaparib como tratamiento adyuvante en pacientes con cáncer de mama HER2 negativo de alto riesgo y mutaciones germinales de BRCA1/2 Efficacy of adjuvant treatment with olaparib on Invasive Disease Free Survival (IDFS). evaluar el efecto del tratamiento adyuvante con olaparib sobre la supervivencia libre de enfermedad infiltr...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune